Close

PhaseRx (PZRX) Granted Orphan Drug Status for PRX-ASL to Treat ASLD

September 20, 2017 2:10 PM EDT Send to a Friend
PhaseRx, Inc. (NASDAQ: PZRX) today announced that its second drug development candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login